Call us 24/7

Clinical trials

Filters

33 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A Phase 2, multi-center, open-label, two-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem]) in patients with unresectable, locally advanced, recurrent or metastatic biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer), who are naïve to tumor-directed therapy in the locally advanced or metastatic setting, and for which treatment with 1L therapy (defined as a combination of cis/gem) is planned.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to assess the efficacy and safety of pembrolizumab vsersus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to determine if the study drug talazoparib (also called BMN 673) is safe when given as a breast cancer treatment and to evaluate how cancer responds to it.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) (the “study drug”) with two approved drugs (capecitabine and trastuzumab) in participants with advanced breast cancer to find out what effects, good or bad, it may have on the participants and their disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 3 multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post-menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

In phase 2, the selected combined dose level of AGEN2034 and AGEN1884, established in part A, will be administered for a maximum of two years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drugs or withdrawal from the trial occurs. Cancer Treatment Centers of America® (CTCA) is participating in phase 2, part B: Cervical.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this open-label study is to determine the effects of TGR-1202 in patients with relapsed or refractory follicular lymphoma.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least three lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.